Core Viewpoint - The company reported a significant decline in both sales revenue and profit for the first half of 2025, indicating potential challenges in its business operations and market conditions [1] Financial Performance - Sales revenue for the first half of 2025 was approximately 2.147 billion HKD, a year-on-year decrease of about 35.7% [1] - Profit attributable to equity holders was approximately 283.5 million HKD, down 58.7% year-on-year [1] - Earnings per share were 0.0962 HKD, with an interim dividend of 0.05 HKD compared to 0.08 HKD in the same period last year [1] Business Segments - The infusion business experienced a significant decline, with sales volume of approximately 715 million bottles (bags), a year-on-year decrease of 37%, and sales revenue of 1.199 billion HKD, down 45% [1] - In the water injection segment, ampoule water injection sales volume was 17.818 million units, a year-on-year increase of 7%, but sales revenue fell to 157 million HKD, a decrease of 57% [1] - The oral formulation segment saw a sales revenue of 296 million HKD, reflecting a year-on-year growth of 16% [1] - The active pharmaceutical ingredients segment reported sales revenue of 361 million HKD, down 9.6% year-on-year [1]

石四药集团(02005)午后跌超5%，截至发稿，跌5.74%，报2.79港元，成交额5386.67万港元。 输液业务方面，上半年，输液产销量整体均呈现较大幅度的下降，其中，销售量实现约7.15亿瓶(袋)， 同比下降37%；实现销售收入11.99亿港元，同比下降 45%。水针业务方面，上半年，安瓿水针销量 17,818万支，同比增长7%；销售额1.57亿港元，同比下降57%。口服制剂业务方面，上半年口服制剂实 现销售额2.96亿港元，同比增长16%。原料药业务方面，上半年原料药实现销售额3.61亿港元，同比下 降 9.6%。 消息面上，石四药集团午间公布2025年中期业绩，上半年销售收入约21.47亿港元，同比下降约35.7%； 公司股权持有人应占溢利约2.835亿港元，同比下降约58.7%；每股盈利0.0962港元，派中期息5港仙， 上年同期派8港仙。 ...

Core Viewpoint - The company reported a significant decline in sales and profits for the first half of 2025, with a focus on adapting to market challenges and enhancing product offerings to stabilize its market position [1][2][3][4] Group 1: Financial Performance - The company achieved sales revenue of approximately HKD 2.147 billion, a year-on-year decrease of about 35.7% [1] - Profit attributable to equity holders was approximately HKD 283.5 million, down 58.7% year-on-year [1] - Earnings per share were HKD 0.0962, with an interim dividend of HKD 0.05 per share [1] Group 2: Infusion Business - The infusion sales volume decreased significantly, with approximately 715 million bottles (bags) sold, a decline of 37% year-on-year [1] - Sales revenue from infusion products was HKD 1.199 billion, down 45% year-on-year [1] - The company is focusing on digital transformation and market segmentation to enhance the sales of therapeutic infusion products [1] Group 3: Injectable and Oral Formulations - The sales volume of ampoule water injections increased by 7% to 17.818 million units, but sales revenue fell by 57% to HKD 157 million [2] - Notable growth in specific injectable products included a 61% increase in sales of mecobalamin injections and a 198% increase in sales of nebulized terbutaline solution [2] - Oral formulations achieved sales of HKD 296 million, a 16% increase year-on-year, with significant contributions from new products and contract renewals [2] Group 4: API and Export Business - The active pharmaceutical ingredients (API) segment saw sales of HKD 361 million, a decline of 9.6% year-on-year, with caffeine sales down 15% [3] - The company reported a 42% increase in export volume for infusion products, with a total of 7.361 million bottles (bags) exported [3] - The export sales of oral formulations reached a record high, with a staggering 9958% increase year-on-year [3] Group 5: Packaging Materials - The sales of pharmaceutical packaging materials reached HKD 101 million, reflecting a 7.1% year-on-year growth [4] - The company is enhancing its product offerings in rubber stoppers and multi-layer co-extruded films to improve market penetration [4]

Core Viewpoint - The company reported a significant decline in sales and profits for the first half of 2025, with a focus on adapting to market challenges and enhancing product offerings to stabilize its business performance [1][2][3][4] Group 1: Financial Performance - The company achieved sales revenue of approximately HKD 21.47 billion, a year-on-year decrease of about 35.7% [1] - Profit attributable to equity holders was approximately HKD 283.5 million, down about 58.7% year-on-year [1] - Earnings per share were HKD 0.0962, with an interim dividend of HKD 0.05 per share [1] Group 2: Business Segments Infusion Business - Infusion sales volume decreased to approximately 715 million bottles (bags), a decline of 37% year-on-year, with sales revenue of HKD 1.199 billion, down 45% [1] - The company is focusing on product matrix development and digital transformation to enhance market positioning [1] Injectable Business - Ampoule water needle sales volume reached 17.818 million units, a year-on-year increase of 7%, but sales revenue fell by 57% to HKD 157 million [2] - Notable growth in specific products: Methylcobalamin injection sales increased by 61%, and Urapidil hydrochloride injection sales rose by 28% [2] Oral Formulations - Oral formulations achieved sales of HKD 296 million, a year-on-year increase of 16% [2] - New products contributed significantly, with sales of specific items like Rosuvastatin calcium tablets increasing by 32% [2] API Business - API sales amounted to HKD 361 million, a decline of 9.6% year-on-year, with caffeine sales down 15% [3] - The company is enhancing international collaborations and product registrations to mitigate market challenges [3] Export Business - The company reported a 42% increase in export volume for infusions, with significant growth in ampoule water needle and oral formulation exports [3] - The total export sales reached RMB 100.45 million, reflecting a 42% year-on-year increase [3] Packaging Materials - Sales of pharmaceutical packaging materials reached HKD 101 million, a year-on-year increase of 7.1% [4] - The company is focusing on enhancing its product offerings to meet market demands [4]

Group 1 - The company reported a sales revenue of approximately 1.976 billion RMB for the first half of 2025, representing a year-on-year decline of about 35% [1] - In HKD terms, the sales revenue for the first half of this year was approximately 2.147 billion HKD, also reflecting a year-on-year decrease of about 36% [1] - The net profit for the company was approximately 284 million HKD, which is a year-on-year decline of 58.7% [1] Group 2 - The total gross profit recorded by the group was 890 million HKD, down from 1.843 billion HKD in the same period last year [1] - The overall gross margin decreased by 13.7 percentage points from 55.2% in the previous year to 41.5% [1] - The decline in average selling prices of existing intravenous and ampoule injection products, along with a higher proportion of revenue from centralized procurement sales, contributed to the changes in gross profit and margin [1]

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 石四藥集團有限公司 | | 股份代號 | 02005 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 截至二零二五年六月三十日止六個月之中期股息 | | | 公告日期 | 2025年8月28日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 | 每 股 0.05 HKD | | 股東批准日期 | 不適用 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.05 HKD | | 匯率 | 1 HKD : 1 HKD | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何部份內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：2005） 截至二零二五年六月三十日止六個月 中期業績公佈 主席報告 本人謹代表石四藥集團有限公司（「公司」）董事局（「董事局」），呈報公司及其附屬公司（簡稱 「集團」）截至二零二五年六月三十日止六個月（「上半年」）的未經審核中期業績。 等6個產品准入省份均超20個，醋酸鈉林格葡萄糖注射液、伏立康唑乾混懸劑等4 個產品准入省份均超15個，產品的市場准入覆蓋率持續提升，為後續業績增長奠 定了堅實基礎。 一、業績及派息 2025年上半年，外部環境更趨複雜嚴峻，集團經營面臨國內外需求增長動力不足、產品 價格持續下滑、產業政策不斷深化調整等挑戰。面對業績階段性承壓，集團堅定信心、 攻堅克難，持續深化創新驅動戰略，優化產品結構，鞏固並拓展市場份額，努力夯實經 濟回升向好基礎，以發展的確定性應對外部環境的不確定性。 今年上半年實現銷售收入以人民幣計約19.76億元，同比 ...

Group 1 - The company, Stone Four Pharmaceutical Group, has obtained the production registration approval from the National Medical Products Administration of China for Benidipine Hydrochloride Tablets (8mg) [1] - The product is classified as a Class 4 chemical drug and is considered to have passed the consistency evaluation [1] - Benidipine Hydrochloride Tablets are primarily used for the treatment of primary hypertension and angina pectoris [1] Group 2 - The raw material for Benidipine Hydrochloride has also been approved by the National Medical Products Administration for use in the marketed formulation [1]

8月25日午间，石四药集团在港交所公告，集团已取得中国国家药监局有关盐酸贝尼地平片（8mg）的 药品生产注册批件，属于化学药品第4类，视同通过一致性评价。盐酸贝尼地平片主要用于治疗原发性 高血压和心绞痛。 ...

石四药集团(02005)发布公告，本集团已取得中国国家药品监督管理局(国家药监局)有关盐酸贝尼地平片 (8mg)的药品生产注册批件，属于化学药品第4类，视同通过一致性评价。 盐酸贝尼地平片主要用于治疗原发性高血压和心绞痛。诚如本公司日期为2025年1月6日的公告所载，本 集团的盐酸贝尼地平原料药已获国家药监局批准登记成为在上市制剂使用的原料药。 ...